Fuad Makkouk, MD
Ophthalmology · Austin, TXNPI 1023454386
Payments from drug & device makers
Across 1,607 payments — averaging $4109.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3.9M
- Novartis$1.3M
- Boehringer Ingelheim$523K
- Boehringer Ingelheim International GmbH$455K
- Kyowa Kirin, Inc.$199K
- Janssen Research & Development, LLC$86K
- plus $171K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 872 | $3,908,193 |
| Novartis | 22 | $1,261,282 |
| Boehringer Ingelheim | 73 | $523,334 |
| Boehringer Ingelheim International GmbH | 375 | $455,087 |
| Kyowa Kirin, Inc. | 106 | $198,688 |
| Janssen Research & Development, LLC | 34 | $86,097 |
| Apellis Pharmaceuticals, Inc. | 40 | $68,298 |
| AstraZeneca | 2 | $40,814 |
| Sanofi US Services Inc. | 3 | $21,342 |
| AbbVie | 13 | $18,167 |
| Regeneron | 3 | $12,947 |
| Genentech USA, Inc. | 28 | $7,717 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $332 |
| Regeneron Healthcare Solutions, Inc. | 12 | $328 |
| Optos, Inc. | 2 | $243 |
| Biotissue Holdings Inc. | 3 | $211 |
| Alcon | 1 | $143 |
| Amgen | 2 | $138 |
| Harrow Eye, LLC | 3 | $129 |
| Bausch & Lomb Americas Inc. | 2 | $126 |
| Rxsight Inc | 1 | $81 |
| Alimera Sciences, Inc. | 1 | $42 |
| Biogen | 2 | $37 |
| Astellas Pharma Global Development | 1 | $27 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $18 |
How this compares
$6,603,842 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Austin
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Philip StoreyAustin$2.1M
- Saradha ChexalAustin$1.8M
- James DoonerAustin$556K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.